Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.61)
# 3,940
Out of 4,944 analysts
55
Total ratings
28.57%
Success rate
-28.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.60 | +96.43% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $19.20 | +61.46% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.28 | +1,384.38% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $4.50 | +366.67% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $3.17 | +57.73% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.25 | +1,180.00% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $5.29 | +2,168.43% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $8.04 | +210.95% | 2 | May 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $6.99 | +28,512.30% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.44 | +386.11% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.47 | +580.27% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $11.10 | +440.54% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.10 | +445.45% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $5.30 | +88.68% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.75 | +31,900.00% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $8.81 | +1,965.83% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.22 | +36,148.30% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.47 | +709.72% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.84 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.96 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.38 | +152.10% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.62 | +217.46% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $7.21 | +145,531.07% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.77 | +1,235.74% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $23.60 | +1,171.19% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $556.56 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $81.61 | +9.06% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $128.89 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.55 | +181,718.18% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.49 | +22,450.34% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.39 | +430.97% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.60
Upside: +96.43%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $19.20
Upside: +61.46%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.28
Upside: +1,384.38%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $4.50
Upside: +366.67%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $3.17
Upside: +57.73%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.25
Upside: +1,180.00%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $5.29
Upside: +2,168.43%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $8.04
Upside: +210.95%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $6.99
Upside: +28,512.30%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.44
Upside: +386.11%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.47
Upside: +580.27%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $11.10
Upside: +440.54%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.10
Upside: +445.45%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $5.30
Upside: +88.68%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.75
Upside: +31,900.00%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $8.81
Upside: +1,965.83%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.22
Upside: +36,148.30%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $2.47
Upside: +709.72%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.84
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.38
Upside: +152.10%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.62
Upside: +217.46%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $7.21
Upside: +145,531.07%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.77
Upside: +1,235.74%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $23.60
Upside: +1,171.19%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $556.56
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $81.61
Upside: +9.06%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $128.89
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.55
Upside: +181,718.18%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.49
Upside: +22,450.34%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.39
Upside: +430.97%